|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 35/15 | (2015.01) |
| C12N 5/0786 | (2010.01) | ||
| A61K 39/00 | (2006.01) |
| (11) | Number of the document | 3999080 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20740038.3 |
| Date of filing the European patent application | 2020-07-17 | |
| (97) | Date of publication of the European application | 2022-05-25 |
| (45) | Date of publication and mention of the grant of the patent | 2023-07-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2020/070379 |
| Date | 2020-07-17 |
| (87) | Number | WO 2021/013764 |
| Date | 2021-01-28 |
| (30) | Number | Date | Country code |
| 19305963 | 2019-07-19 | EP |
| (72) |
PERFETTINI, Jean-Luc , FR
ALLOUCH, Awatef , FR
DEUTSCH, Eric , FR
|
| (73) |
Institut Gustave-Roussy ,
39, rue Camille Desmoulins, 94800 Villejuif,
FR
|
| (54) | P21 EXPRESSING MONOCYTES FOR CANCER CELL THERAPY |
| P21 EXPRESSING MONOCYTES FOR CANCER CELL THERAPY |